NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy
March 15 2019 - 8:30AM
via NetworkWire – NetworkNewsAudio announces the Audio Press
Release (APR) titled “Making Profits, Saving Lives with Gene
Therapy,” featuring Genprex Inc. (GNPX).
To hear the NetworkNewsAudio version, visit:
http://nnw.fm/bw1cX
To read the full editorial, visit: http://nnw.fm/Y0ZqH
Delivery systems for the genes are as important as the genes
themselves. Carriers called vectors deliver the genetic material
into the cells. These are often viruses, turning a life form that
is hostile to humanity into one that benefits us. In the case of
Genprex’s Oncoprex treatment, the genes are carried in an
intravenously delivered nanovesicle, or a tiny compartment like
those found in cells. The Oncoprex nanovesicle is small enough to
cross barriers into the lungs, where it can deliver its genetic
material to the cancer site.
This uses one of two forms of gene therapy: gene replacement
therapy. Currently, gene replacement therapies are the only ones
approved by the FDA. The alternative, gene editing, has been the
subject of various clinical trials but has not yet led to an
approved treatment. For now, gene replacement therapy, or tackling
unhealthy cells through the addition of healthy genes, is the
proven way forward to gene therapy, and the approach appears to be
serving Genprex well.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex(TM)
immunogene therapy for non-small cell lung cancer (NSCLC).
Genprex’s platform technologies are designed to administer cancer
fighting genes by encapsulating them into nanoscale hollow spheres
called nanovesicles, which are then administered intravenously and
taken up by tumor cells where they express proteins that are
missing or found in low quantities. Oncoprex has a multimodal
mechanism of action whereby it interrupts cell signaling pathways
that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells, and modulates the immune response against cancer
cells. Oncoprex has also been shown to block mechanisms that create
drug resistance. For more information, visit the company’s website
at www.Genprex.com.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution,
allows you to sit back and listen to market updates, CEO interviews
and a Company AudioPressRelease (APR). These audio clips provide
snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024